Irvine Scientific ships first products from plant in Tokyo
Facility produces animal component-free cell culture media
The new facility, located in Saitama prefecture, manufactures animal component-free cell culture media in volume requirements ranging from research use to production of biopharmaceuticals and vaccines. The plant has been commissioned and validated as completely animal component free (ACF).
The new facility, which meets the highest quality cGMP standards, currently occupies 1,720m2 and replicates the production and processes used at the Irvine Scientific’s Santa Ana, CA, US manufacturing facility.
The Tokyo site has state-of-the-art formulation and packaging equipment, and uses continuous milling and blending equipment designed and built to Irvine Scientific specifications. There is room for expansion depending on customer demands.
The Tokyo facility capacity doubles Irvine Scientific’s current powder manufacturing capability at Santa Ana and will bring the total capacity at both sites to more than 1.2 million kilos a year.
Irvine Scientific, a member of JX Holdings group, is a designer, manufacturer and distributor of industrial cell culture, cytogenetic, assisted reproductive technology (ART) and specialist media products. It is a large-scale producer of advanced quality cell culture media for the industrial bioprocess, medical, and diagnostic markets.
You may also like
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Manufacturing
Rentschler Biopharma expands services in Japan and South Korea ahead of BioProcess International Asia
Rentschler Biopharma will showcase its Rentschler Expression Platform and Development Services at BioProcess International Asia in Kyoto, underscoring its commitment to supporting biopharma partners across Japan and South Korea
Distribution
Cold Chain Technologies launches “Smart Chain, Clear Gain” campaign to elevate digitalisation in pharma logistics
Leading temperature-controlled solution provider, Cold Chain Technologies (CCT), has unveiled its new campaign, Smart Chain, Clear Gain, aimed to redefine how pharmaceutical companies approach compliance, efficiency and value in cold chain logistics
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Building resilient outsourcing strategies: safeguarding oncology research samples against disaster risk (part I)
With a focus on the evolving landscape of biorepositories, this article explores the critical importance of robust outsourcing strategies to protect oncology research samples from disaster risk. Lori A. Ball, Chief Executive Officer at Astoriom, reports